Slide 1: Life-Science Products New Generation Pioneering
Life-Science Products NEW GENERATION PIONEERING OFER HAVIV | PRESIDENT & CEO May 23, 2024
Slide 2: Forward-looking statements
This presentation contains "forward-looking statements" relating to future events, and Evogene Ltd. (the “Company”), may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting us that are co
Slide 3: Earnings Call Q1 2024 Agenda
Earnings Call Q1 2024 AGENDA Financial & Business Highlights Evogene Overview Subsidiaries’ Achievements CFO Update / By Yaron Eldad Q&A 3 CEO Update / By Ofer Haviv
Slide 4: Financial and Business Highlights
Financial and Business Highlights: In Q1 2024, total revenues reached approximately $4.2 million compared to $0.6 million in Q1 2023. In full year 2024, anticipated continued revenue growth compared to the previous year. In Q1 2024, loss was approximately $3.8 million compared to $7.0 million in Q1
Slide 5: Financial and Business Highlights
Financial and Business Highlights: Casterra's recent agreements with African and Brazilian seed growers, securing an addition of 900 tons - expected to fulfill all outstanding orders by end of 2024. Biomica to present preliminary phase 1 clinical trial results for BMC128, at the 2024 ASCO conference
Slide 6: Agenda: Evogene Overview
Earnings Call Q1 2024 AGENDA Financial & Business highlights Evogene Overview Subsidiaries’ Achievements CFO Update / By Yaron Eldad Q&A 6 CEO Update / By Ofer Haviv
Slide 7: The Resource Killer: Life-Science Products Long-Tail Process
THE RESOURCE KILLER LIFE-SCIENCE PRODUCTS LONG-TAIL PROCESS > DISCOVERY > OPTIMIZATION > DEVELOPMENT > REGULATION THE CHALLENGE finding the winning candidates out of a vast number of possible prospects that address a complex myriad of criteria, to reach higher success rate for products “Needle in th
Slide 8: Our Mission: Decoding Biology
8 OUR MISSION DECODING BIOLOGY WE MERGE SCIENCE WITH BIG DATA AND CUTTING-EDGE AI TECHNOLOGIES TO EFFECTIVELY DISCOVER AND OPTIMIZE NOVEL LIFE-SCIENCE BASED PRODUCTS.
Slide 9: Our Solution: Computational Predictive Biology Platform
BIG DATA SCIENCE AI OUR SOLUTION The CPB platform, born from over a decade of intensive research and development, fueled by millions of dollars in investment, directs and accelerates life-science product discovery and optimization through dedicated AI Tech-Engines. Computational Predictive Biology 9
Slide 10: Discovery & Optimization: Three AI Tech-Engines
DISCOVERY & OPTIMIZATION WE DIRECT AND ACCELERATE LIFE-SCIENCE PRODUCT through 3 dedicated AI tech-engines MICROBES GENETIC ELEMENTS SMALL MOLECULES The Result: Promising candidates addressing multiple development challenges towards successful life-science-based products. PROBABILITY OF SUCCESS TIME
Slide 11: A World of Opportunities for Our AI Tech Engines
11 SMALL MOLECULES GENETIC ELEMENTS MICROBES AGRICULTURE & FOOD PHARMA & WELLNESS OTHER INDUSTRIES Improvedcrops Alternativefood Medical Cannabis Genetherapy Diagnostics & precisionmedicine Celltherapy Bio fuel Fragrances Natural foodcoloring Novelenzymes AGRICULTURE & FOOD PHARMA & WELLNESS OTHER I
Slide 12: Business Strategy
12 BUSINESS STRATEGY Capture the value of our AI tech-engines through diverse collaborative partnerships to accelerate life-science product development Partnering with experts in specific fields complements our technology, enabling groundbreaking innovations and financial gains for Evogene. EVOGENE
Slide 13: Licensing & Collaboration Current Status
Aquaculture Licensing Collaboration Improved traits - canola Crop protection Pharmaceuticals Microbials for crops Therapeutic microbials 13 LICENSING & COLLABORATION | CURRENT STATUS Food-tech SMALL MOLECULES GENETIC ELEMENTS MICROBES Immuno-oncology program GI related disorders Bio-stimulants Bio-p
Slide 14: Updates: Canonic ceased operations
14 UPDATES Ceased operations, following challenging market conditions in the medical cannabis sector. Estimated annualized savings ~$1.5 million.
Slide 15: Updates: Verb Biotics collaboration
15 UPDATES Collaboration agreement with Verb Biotics for probiotic products, aiming to identify and design bacteria that produce highly sustainable quantities of metabolites, for improved human health and vitality. Synergy of combining Evogene's knowledge in bacterial-based product development (Micr
Slide 16: Updates: Finally Foods
16 UPDATES -Evogene and The Kitchen FoodTech Hub established ‘Finally Foods’, for sustainable protein production in plants for the food sector. - Finally Foods will Leverage Evogene’s GeneRator AI tech-engine. - Pre-seed funding secured from The Kitchen Hub and the Israeli Innovation Authority. - Ev
Slide 17: Agenda: Subsidiaries' Achievements
Earnings Call Q1 2024 AGENDA Financial & Business Highlights Evogene Overview Subsidiaries’ Achievements CFO Update / By Yaron Eldad Q&A 17 CEO Update / By Ofer Haviv
Slide 18: Casterra update
18 Casterra, Evogene’s fully owned subsidiary, focuses on developing an integrated solution for large-scale castor bean cultivation, utilizing GeneRator AI tech-engine. New agreements with seed growers in Africa and Brazil - boost castor seed production by approximately 900 tons in 2024. Expected co
Slide 19: AgPlenus update
19 AgPlenus, a global leader in computational design and development of novel sustainable crop protection products, utilizing ChemPass AI tech-engine - Licensing & collaboration agreement with Bayer to develop herbicides targeting APTH1 protein; Entitled to an upfront payment, ongoing research fundi
Slide 20: Lavie Bio update
20 Lavie Bio, a global leader in developing next generation ag-biological products, leveraging MicroBoost AI tech-engine Agreement with Syngenta for discovery and development of new biological insecticidal solutions. Meeting Corteva's licensing requirements, securing second-half advanced payment of
Slide 21: Biomica update
21 Biomica specializes in developing microbiome-based therapeutics for human health, utilizing Evogene's MicroBoost AI tech-engine Completing Phase I trial enrollment for microbiome-based immuno-oncology drug, BMC128. Preliminary Phase 1 study data of BMC128 to be presented at ASCO 2024 Annual Confe
Slide 22: Group Commercial & Financial Partners
22 Group Commercial & Financial Partners Investment & Collaboration Collaboration Investment & Collaboration Collaboration Collaboration Investment Collaboration Collaboration Collaboration Collaboration Collaboration
Slide 23: Agenda: CFO Update
Earnings Call Q1 2024 AGENDA Financial & Business Highlights Evogene Overview Subsidiaries’ Achievements CFO Update / By Yaron Eldad Q&A 23 CEO Update / By Ofer Haviv
Slide 24: CFO Update: Balance Sheet
WE CFO UPDATE CURRENT ASSETS: ‘Cash and cash equivalents ‘Short-term bank deposits Trade receivables Other receivables and prepaid expenses Inventories LONG-TERM ASSETS: Long-term deposits and other receivables Investment accounted for using the equity method Rightof-use-assets Property, plant and e
Slide 25: CFO Update: Evogene Financial Performance Q1 2024
CFO UPDATE Evogene Financial Performance Q1 2024 Three months ended March 31, Year ended December 31, 2024 2023 2023 Unaudited Audited Revenues $ 4,190 $ 641 $ 5,640 Cost of revenues 310 322 1,692 Gross profit 3,880 319 3,948 Operating expenses: Research and development, net 4,801 4,800 20,777 Sales
Slide 26: Agenda: Q&A
Earnings Call Q1 2024 AGENDA Financial & Business Highlights Evogene Overview Subsidiaries’ Achievements CFO Update / By Yaron Eldad Q&A 26 CEO Update / By Ofer Haviv
Slide 27: Thank You
} THANK YOU